Carisma Therapeutics Inc.
CARMOTCHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $19.6M | $14.9M | $9.8M | $26.5M | $11.2M | $0 |
| Operating income | −$62.2M | −$88.7M | −$56.2M | −$8.5M | −$21.1M | −$108.5M |
| Net income | −$60.5M | −$86.9M | −$61.2M | −$336,000 | −$22.4M | −$107.5M |
| Total assets | $30.5M | $89.6M | $72.2M | $240.7M | $122.8M | $114.4M |
| Total liabilities | $58.4M | $63.0M | $107.0M | $69.0M | $132.1M | $141.1M |
| Equity | −$27.9M | $26.5M | −$157.1M | $171.7M | −$9.2M | −$26.7M |
| EPS (diluted) | $-1.46 | $-2.59 | $-28.77 | $0.00 | $-0.19 | $-1.18 |
| Shares out. | 41.5M | 203.5M | 199.5M | 167.6M | 110.0M | 77.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −317.2%
- Net margin
- −308.6%
- Return on equity
- 216.7%
- Return on assets
- −198.6%
- Return on capital (ROCE)
- −431.7%
- Liabilities / assets
- 191.6%
- Debt / equity
- —
- Book value / share
- $-0.67
- Revenue growth (YoY)
- 31.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -45.25distress
- Accruals / assets
- −1.8%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 15, 2017
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Healthcap Vii, L.P.Activist (13D)Sep 2, 2025
- Abbvie Biotechnology LtdPassive (13G)Apr 25, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Klichinsky MichaelOfficer — Chief Scientific Officer | Oct 7, 2025 | Option exercise | 56,982 | $0.11 |
| Klichinsky MichaelOfficer — Chief Scientific Officer | Oct 1, 2025 | Sell | 165,000 | $0.26 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6,663 | 1.0 | 0.0% |
| Apr 30, 2026 | 6,663 | 1.0 | 0.0% |
| Apr 15, 2026 | 6,663 | 1.0 | 0.0% |
| Mar 31, 2026 | 6,663 | 1.0 | -9.0% |
| Mar 13, 2026 | 7,324 | 1.0 | -26.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard notice · Director / officer changeDec 5, 2025
- Director / officer changeOct 15, 2025
- Delisting / listing-standard noticeOct 9, 2025
- Entered a material agreement · Terminated a material agreement · Other material eventSep 18, 2025
- Entered a material agreement · Unregistered equity sale · Change in control · Director / officer change · Other material eventAug 29, 2025
- Shareholder voteAug 8, 2025
- Delisting / listing-standard noticeJul 15, 2025
- Entered a material agreement · Regulation FD disclosureJun 23, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.